ImmUniverse or “Better control and treatment of immune-mediateddiseases by exploring the universe of microenvironment imposed tissue signatures and theircorrelates in liquid biopsies” or is a project seeking to improve diagnostic and therapeutic options for patients living with immune-mediated inflammatory diseases, including atopic eczema. EFA coordinates a Patient Input Platform (PIP) together with the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA). The PIP is composed of 15 patients with atopic eczema and ulcerative colitis from 11 European countries, including members from EFA’s Atopic Eczema Working Group.

In 2022, EFA continued to work to ensure the patient centricity of the research, setting the basis for a stronger participation of the PIP throughout the project and a deeper involvement of patients in the research. In May, the PIP was involved in a meeting with the Principal Investigators (PIs) of the consortium. In June, a EFA representative joined the the first in-person Consortium Annual Meeting in Milan (Italy).  Besides the planned online and in-person meetings, the PIP was also consulted throughout the year.

ImmUniverse: diagnosis and treatment for Atopic Eczema

Consortium: 26 organisations

Countries: Italy, Switzerland, France, Belgium, Austria, Netherlands, Germany, Denmark, Luxembourg, and United Kingdom

Research with an EFA/EFCCA led Patient Input Platform (PIP) of 15 individuals

Funded by Innovative Medicines Initiative (IMI2) No. 853995

1 January 2020 – 31 December 2025 - 60 months

Website / X (Twitter)